-
公开(公告)号：EP2341060B1
公开(公告)日：2019-02-20
申请号：EP10010679.8
申请日：2001-12-12
-
2.发明公开Molecules with extended half-lives, compositions and uses thereof 有权新泽西州的MUSA MITLÄNGERENHALBWERTSZEITEN，ZUSAMMENSETZUNGEN UND DEREN VERWENDUNG
公开(公告)号：EP2354149A1
公开(公告)日：2011-08-10
申请号：EP10010680.6
申请日：2001-12-12
CPC分类号： C07K16/283 , A61K38/00 , A61K39/00 , A61K47/48507 , A61K47/6835 , A61K49/0002 , A61K49/0004 , A61K2039/505 , C07K2/00 , C07K14/70503 , C07K16/00 , C07K2317/14 , C07K2317/21 , C07K2317/24 , C07K2317/52 , C07K2317/53 , C07K2317/94 , C07K2319/00 , C07K2319/30 , Y10S435/81
摘要： The present invention provides molecules, including IgGs, non-lgG immunoglobulins, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules.
摘要翻译： 本发明提供了由于存在IgG恒定结构域或其结合FcRn的部分而具有增加的体内半衰期的IgG，非IgG免疫球蛋白，蛋白质和非蛋白质试剂的分子，其具有一个 或更多的增加FcRn的恒定结构域或片段的亲和力的氨基酸修饰。 具有增加的半衰期的这种蛋白质和分子具有在这种分子的治疗，预防或诊断中使用较少量和/或更少频率给药的优点。
-
公开(公告)号：EP2357187A1
公开(公告)日：2011-08-17
申请号：EP10010681.4
申请日：2001-12-12
CPC分类号： C07K16/283 , A61K38/00 , A61K39/00 , A61K47/48507 , A61K47/6835 , A61K49/0002 , A61K49/0004 , A61K2039/505 , C07K2/00 , C07K14/70503 , C07K16/00 , C07K2317/14 , C07K2317/21 , C07K2317/24 , C07K2317/52 , C07K2317/53 , C07K2317/94 , C07K2319/00 , C07K2319/30 , Y10S435/81
摘要： The present invention provides molecules, including IgGs, non-IgG immunoglobulins, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules.
摘要翻译： 本发明提供由于存在IgG恒定结构域或其结合FcRn的部分而具有增加的体内半衰期的分子，包括IgG，非IgG免疫球蛋白，蛋白质和非蛋白质剂，所述分子具有一个 或更多增加恒定结构域或片段对FcRn的亲和力的氨基酸修饰。 具有增加的半衰期的此类蛋白质和分子具有在治疗，预防或诊断使用此类分子时需要更少量和/或更少频率给药的优点。
-
4.发明公开Molecules with extended half-lives, compositions and uses thereof 审中-公开MolekülemitlängerenHalbwertszeiten，Zusammensetzungen und deren Verwendung
公开(公告)号：EP2341060A1
公开(公告)日：2011-07-06
申请号：EP10010679.8
申请日：2001-12-12
CPC分类号： C07K16/283 , A61K38/00 , A61K39/00 , A61K47/6835 , A61K49/0002 , A61K49/0004 , A61K2039/505 , C07K2/00 , C07K14/70503 , C07K16/00 , C07K2317/14 , C07K2317/21 , C07K2317/24 , C07K2317/52 , C07K2317/53 , C07K2317/94 , C07K2319/00 , C07K2319/30 , Y10S435/81
摘要： The present invention provides molecules, including IgGs, non-IgG immunoglobulins, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules.
摘要翻译： 本发明提供了由于存在IgG恒定结构域或其结合FcRn的部分而具有增加的体内半衰期的分子，包括IgG，非IgG免疫球蛋白，蛋白质和非蛋白质试剂，其具有一个 或更多的增加FcRn的恒定结构域或片段的亲和力的氨基酸修饰。 具有增加的半衰期的这种蛋白质和分子具有在这种分子的治疗，预防或诊断中使用较少量和/或更少频率给药的优点。
-
-
-
搜索结果
4 条记录 (耗时 0.017 秒)
